Loading…

Analysis of Transition from Intravenous Iron Sucrose to Ferric Carboxymaltose Infusions in Pediatric Intestinal Failure Patients

Iron supplementation is required for pediatric patients with intestinal failure (IF). There is a paucity of literature on optimal iron formulation and outcomes in this patient population that requires ongoing supplementation. The aim of this study was to assess outcomes in pediatric patients with IF...

Full description

Saved in:
Bibliographic Details
Published in:JPEN. Journal of parenteral and enteral nutrition 2022-05
Main Authors: Kaenkumchorn, Tanyaporn K, Rosete, Beatrice E, Carlin, Kristen, Fukasawa, Shiho, Horslen, Simon P, Wendel, Danielle
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Iron supplementation is required for pediatric patients with intestinal failure (IF). There is a paucity of literature on optimal iron formulation and outcomes in this patient population that requires ongoing supplementation. The aim of this study was to assess outcomes in pediatric patients with IF receiving iron sucrose (IS) versus ferric carboxymaltose (FCM) iron infusions. This was a single-center observational cohort study of pediatric patients with IF requiring ongoing intravenous iron supplementation. Patients were transitioned from IS to FCM as iron therapy. Longitudinal linear mixed-effects models and generalized estimating equations were used to compare outcomes including hematologic, iron, and growth parameters for 12 months treatment duration on each iron formulation. Adverse effects were descriptively summarized. Twenty-three patients were included. Sixteen received IS and later switched to FCM, 5 received IS only, and 2 received FCM only. Most patients' etiology of IF was short bowel syndrome (FCM: 81%, IS: 83%). No differences were seen over time for iron, hematologic, and growth metrics between IS and FCM. The median number of infusions over 12 months for those taking IS was 15 (IQR = 13 - 26) and 2 for FCM (IQR = 1 - 2). Asymptomatic hypophosphatemia was noted in both groups. Similar central line associated blood steam infection rates were noted. IS and FCM infusions both maintained hematologic and iron parameters with no significant difference noted between the two types of iron though the number of FCM infusions was significantly less. No significant adverse effects were noted. Pediatric patients with intestinal failure dependent on parenteral nutrition require ongoing iron supplementation. Though there are a variety of iron formulations available, there is a paucity of literature on how iron should be administered in this patient population. Practice varies widely among different institutions. In this study, pediatric patients with intestinal failure were transitioned from iron sucrose to ferric carboxymaltose infusions, and laboratory and clinical outcomes were compared. We found that patients had comparable hematologic and iron parameters with significantly fewer infusions needed in the ferric carboxymaltose group. No significant adverse effects were noted in either group. This article is protected by copyright. All rights reserved.
ISSN:1941-2444